Across 13 Spanish primary-care centers, 135 adults with type 2 diabetes and obesity showed significant improvements in quality of life after 44 weeks of GLP-1 receptor agonist therapy. The EQ-5D quality-of-life index rose from 0.71 to 0.79—an 11% improvement—while patients reported better mobility, reduced pain, and less anxiety. Those achieving at least 5% weight loss experienced the most pronounced benefits across multiple quality-of-life domains. This real-world evidence fills a crucial gap between clinical trial efficacy and practical patient experience. While randomized trials focus primarily on metabolic endpoints like HbA1c and weight loss, this study demonstrates that GLP-1 medications deliver meaningful improvements in day-to-day functioning that patients actually feel. The finding that subcutaneous semaglutide improved physical functioning while oral semaglutide enhanced mental health components suggests different formulations may offer distinct quality-of-life advantages. However, the 44-week timeframe remains relatively short for chronic disease management, and the single-arm design lacks a control group. The results support integrating patient-reported outcomes into routine diabetes care, moving beyond laboratory values to measure what ultimately matters most to patients living with these conditions.